Candidiasis Market Growth
Candidiasis, commonly known as thrush, is a fungal infection caused by a yeast
(a type of fungus) called Candida. It commonly affects the mouth, throat, and
vagina. Risk factors for candidiasis include a weakened immune system due to
HIV/AIDS, cancer treatment, or antibiotics use. Candidiasis if left untreated
can spread to other body parts and become life threatening. The global
candidiasis market growth can be attributed to the increasing demand for
therapeutic drugs to treat drug-resistant strains of Candida and rising prevalence
of hospital-acquired infections.
The Global Candidiasis Market is estimated to be
valued at US$ 1134.49 Bn in 2024 and
is expected to exhibit a CAGR of 8.8% over
the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the Candidiasis market are Basilea Pharmaceutica Ltd,
Astellas Pharma Inc., SCYNEXIS, Inc., NovaDigm Therapeutics, Mycovia
Pharmaceuticals, Inc., Pfizer Inc, and Viatris Inc., among others. The key
opportunities in the candidiasis market include the development of novel
therapeutic drug classes targeting resistant strains and development of
diagnostic tests for early detection. Rising prevalence of hospital-acquired
candidiasis in developing regions presents lucrative opportunities for global
expansion through strategic collaborations and licensing agreements.
Market Drivers and Restrain
The rising prevalence of hospital-acquired infections is one of the major Candidiasis
Market Growth drivers fueling the candidiasis market growth. According
to the Centers for Disease Control and Prevention (CDC), over 700,000 cases of
hospital-acquired infections occur annually in the United States. Moreover, the
ongoing COVID-19 pandemic has severely compromised the immune systems of
patients, further increasing their susceptibility to opportunistic infections.
This has resulted in a significant rise in hospital-acquired candidiasis
globally. However, the availability of generic antifungal drugs and
self-medication are some of the key factors hampering the market growth.
Furthermore, the presence of alternative treatment options also poses a major
challenge.
Segment Analysis
The candidiasis market can be segmented based on treatment type into antifungal
drugs and antifungal vaccines. Among these, antifungal drugs dominate the
market owing to a larger patient pool being treated with various drugs for
candidiasis infections. Some of the commonly used antifungal drug classes
prescribed are azoles, allylamines, and polyenes. Flucytosine is also
prescribed in combinations with other drugs for severe systemic fungal
infections.
Global Analysis
Regionally, North America holds the largest share in the candidiasis market due
to increased per capita healthcare expenditure and higher diagnosis and
treatment rates for fungal infections. However, Asia Pacific is anticipated to
grow at the fastest pace during the forecast period owing to rising awareness
about fungal diseases, increasing healthcare expenditures, and expanding
medical tourism industry in the region. Additionally, presence of leading
global market players is further expected to boost regional market growth in
Asia Pacific through to 2031.
Get More Insights On This Topic: Candidiasis Market